Skip to main content
NCBI home page
Journal of Virology logoLink to Journal of Virology
. 1995 Aug;69(8):4872–4879. doi: 10.1128/jvi.69.8.4872-4879.1995

Specific cytotoxic T lymphocytes recognize the immediate-early transactivator Zta of Epstein-Barr virus.

C Bogedain 1, H Wolf 1, S Modrow 1, G Stuber 1, W Jilg 1
PMCID: PMC189301  PMID: 7609055

Abstract

We identified the immediate-early transactivator Zta of Epstein-Barr virus as a target for specific cytotoxic T lymphocytes (CTL). Cells pulsed with overlapping synthetic peptides representing the entire amino acid sequence of Zta proved to be efficient for the in vitro stimulation of Zta-specific CTL in several donors. With peptide-pulsed target cells, we found that CTL from several donors recognize a peptide comprising 15 amino acids. The immune response against this peptide exerted by CTL lines from different donors was found to be restricted by two different molecules of the major histocompatibility complex: HLA-B8 and HLA-Cw6. The latter molecule could for the first time be identified as a restricting element for a CTL response. The epitope of the HLA-B8-restricted CTL could be mapped to an octameric sequence between amino acid positions 190 and 197 of the Zta protein, whereas the minimal epitope of HLA-Cw6-restricted CTL consists of 11 to 15 residues between positions 187 and 201. Thus, the HLA-B8 and HLA-Cw6 epitopes widely overlap but are not completely identical. In vitro stimulation of blood lymphocytes from a panel of HLA-B8-positive or HLA-Cw6-positive virus carriers, using autologous cells pulsed with the Zta peptides comprising the HLA-B8 or HLA-Cw6 epitope, respectively, revealed in both cases that most of these donors developed a Zta-specific cytotoxic activity. These data, as well as the high spread of the major histocompatibility complex molecules HLA-B8 and HLA-Cw6 in most populations, suggest that an efficient CTL response directed against gene products of the immediate-early group of the lytic cycle exists in vivo in a considerable portion of virus carriers. A CTL response against proteins expressed immediately after the switch into the lytic cycle could eliminate lytically activated cells at an early stage and would thus efficiently prevent the production and release of progeny virions.

Full Text

The Full Text of this article is available as a PDF (275.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arvin A. M., Sharp M., Smith S., Koropchak C. M., Diaz P. S., Kinchington P., Ruyechan W., Hay J. Equivalent recognition of a varicella-zoster virus immediate early protein (IE62) and glycoprotein I by cytotoxic T lymphocytes of either CD4+ or CD8+ phenotype. J Immunol. 1991 Jan 1;146(1):257–264. [PubMed] [Google Scholar]
  2. Barnstable C. J., Bodmer W. F., Brown G., Galfre G., Milstein C., Williams A. F., Ziegler A. Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens-new tools for genetic analysis. Cell. 1978 May;14(1):9–20. doi: 10.1016/0092-8674(78)90296-9. [DOI] [PubMed] [Google Scholar]
  3. Becker J., Leser U., Marschall M., Langford A., Jilg W., Gelderblom H., Reichart P., Wolf H. Expression of proteins encoded by Epstein-Barr virus trans-activator genes depends on the differentiation of epithelial cells in oral hairy leukoplakia. Proc Natl Acad Sci U S A. 1991 Oct 1;88(19):8332–8336. doi: 10.1073/pnas.88.19.8332. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bodmer H. C., Gotch F. M., McMichael A. J. Class I cross-restricted T cells reveal low responder allele due to processing of viral antigen. Nature. 1989 Feb 16;337(6208):653–655. doi: 10.1038/337653a0. [DOI] [PubMed] [Google Scholar]
  5. Bogedain C., Alliger P., Schwarzmann F., Marschall M., Wolf H., Jilg W. Different activation of Epstein-Barr virus immediate-early and early genes in Burkitt lymphoma cells and lymphoblastoid cell lines. J Virol. 1994 Feb;68(2):1200–1203. doi: 10.1128/jvi.68.2.1200-1203.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Borysiewicz L. K., Hickling J. K., Graham S., Sinclair J., Cranage M. P., Smith G. L., Sissons J. G. Human cytomegalovirus-specific cytotoxic T cells. Relative frequency of stage-specific CTL recognizing the 72-kD immediate early protein and glycoprotein B expressed by recombinant vaccinia viruses. J Exp Med. 1988 Sep 1;168(3):919–931. doi: 10.1084/jem.168.3.919. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Chang Y. N., Dong D. L., Hayward G. S., Hayward S. D. The Epstein-Barr virus Zta transactivator: a member of the bZIP family with unique DNA-binding specificity and a dimerization domain that lacks the characteristic heptad leucine zipper motif. J Virol. 1990 Jul;64(7):3358–3369. doi: 10.1128/jvi.64.7.3358-3369.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Chang Y., Chen M. I., Wu R., Chang P., Shu C., Liu S. Sequence analysis of the BZLF 1 gene of Epstein-Barr virus derived from a new variant isolated in Taiwan. Nucleic Acids Res. 1992 Jan 11;20(1):139–139. doi: 10.1093/nar/20.1.139. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Countryman J., Miller G. Activation of expression of latent Epstein-Barr herpesvirus after gene transfer with a small cloned subfragment of heterogeneous viral DNA. Proc Natl Acad Sci U S A. 1985 Jun;82(12):4085–4089. doi: 10.1073/pnas.82.12.4085. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Dill O., Kievits F., Koch S., Ivanyi P., Hämmerling G. J. Immunological function of HLA-C antigens in HLA-Cw3 transgenic mice. Proc Natl Acad Sci U S A. 1988 Aug;85(15):5664–5668. doi: 10.1073/pnas.85.15.5664. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Falk K., Rötzschke O., Grahovac B., Schendel D., Stevanović S., Gnau V., Jung G., Strominger J. L., Rammensee H. G. Allele-specific peptide ligand motifs of HLA-C molecules. Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):12005–12009. doi: 10.1073/pnas.90.24.12005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Flemington E., Speck S. H. Autoregulation of Epstein-Barr virus putative lytic switch gene BZLF1. J Virol. 1990 Mar;64(3):1227–1232. doi: 10.1128/jvi.64.3.1227-1232.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Gavioli R., Kurilla M. G., de Campos-Lima P. O., Wallace L. E., Dolcetti R., Murray R. J., Rickinson A. B., Masucci M. G. Multiple HLA A11-restricted cytotoxic T-lymphocyte epitopes of different immunogenicities in the Epstein-Barr virus-encoded nuclear antigen 4. J Virol. 1993 Mar;67(3):1572–1578. doi: 10.1128/jvi.67.3.1572-1578.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Gratama J. W., Oosterveer M. A., Zwaan F. E., Lepoutre J., Klein G., Ernberg I. Eradication of Epstein-Barr virus by allogeneic bone marrow transplantation: implications for sites of viral latency. Proc Natl Acad Sci U S A. 1988 Nov;85(22):8693–8696. doi: 10.1073/pnas.85.22.8693. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Grogan E., Jenson H., Countryman J., Heston L., Gradoville L., Miller G. Transfection of a rearranged viral DNA fragment, WZhet, stably converts latent Epstein-Barr viral infection to productive infection in lymphoid cells. Proc Natl Acad Sci U S A. 1987 Mar;84(5):1332–1336. doi: 10.1073/pnas.84.5.1332. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Johnson R. P., Trocha A., Buchanan T. M., Walker B. D. Identification of overlapping HLA class I-restricted cytotoxic T cell epitopes in a conserved region of the human immunodeficiency virus type 1 envelope glycoprotein: definition of minimum epitopes and analysis of the effects of sequence variation. J Exp Med. 1992 Apr 1;175(4):961–971. doi: 10.1084/jem.175.4.961. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Johnson R. P., Trocha A., Buchanan T. M., Walker B. D. Recognition of a highly conserved region of human immunodeficiency virus type 1 gp120 by an HLA-Cw4-restricted cytotoxic T-lymphocyte clone. J Virol. 1993 Jan;67(1):438–445. doi: 10.1128/jvi.67.1.438-445.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Khanna R., Burrows S. R., Kurilla M. G., Jacob C. A., Misko I. S., Sculley T. B., Kieff E., Moss D. J. Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development. J Exp Med. 1992 Jul 1;176(1):169–176. doi: 10.1084/jem.176.1.169. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Klein G. Epstein-Barr virus strategy in normal and neoplastic B cells. Cell. 1994 Jun 17;77(6):791–793. doi: 10.1016/0092-8674(94)90125-2. [DOI] [PubMed] [Google Scholar]
  20. Koszinowski U. H., Reddehase M. J., Keil G. M., Schickedanz J. Host immune response to cytomegalovirus: products of transfected viral immediate-early genes are recognized by cloned cytolytic T lymphocytes. J Virol. 1987 Jun;61(6):2054–2058. doi: 10.1128/jvi.61.6.2054-2058.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Lee S. P., Thomas W. A., Murray R. J., Khanim F., Kaur S., Young L. S., Rowe M., Kurilla M., Rickinson A. B. HLA A2.1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2. J Virol. 1993 Dec;67(12):7428–7435. doi: 10.1128/jvi.67.12.7428-7435.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Lewin N., Aman P., Masucci M. G., Klein E., Klein G., Oberg B., Strander H., Henle W., Henle G. Characterization of EBV-carrying B-cell populations in healthy seropositive individuals with regard to density, release of transforming virus and spontaneous outgrowth. Int J Cancer. 1987 Apr 15;39(4):472–476. doi: 10.1002/ijc.2910390411. [DOI] [PubMed] [Google Scholar]
  23. Littaua R. A., Oldstone M. B., Takeda A., Debouck C., Wong J. T., Tuazon C. U., Moss B., Kievits F., Ennis F. A. An HLA-C-restricted CD8+ cytotoxic T-lymphocyte clone recognizes a highly conserved epitope on human immunodeficiency virus type 1 gag. J Virol. 1991 Aug;65(8):4051–4056. doi: 10.1128/jvi.65.8.4051-4056.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Mikaélian I., Drouet E., Marechal V., Denoyel G., Nicolas J. C., Sergeant A. The DNA-binding domain of two bZIP transcription factors, the Epstein-Barr virus switch gene product EB1 and Jun, is a bipartite nuclear targeting sequence. J Virol. 1993 Feb;67(2):734–742. doi: 10.1128/jvi.67.2.734-742.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Missale G., Redeker A., Person J., Fowler P., Guilhot S., Schlicht H. J., Ferrari C., Chisari F. V. HLA-A31- and HLA-Aw68-restricted cytotoxic T cell responses to a single hepatitis B virus nucleocapsid epitope during acute viral hepatitis. J Exp Med. 1993 Mar 1;177(3):751–762. doi: 10.1084/jem.177.3.751. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Modrow S., Höflacher B., Mellert W., Erfle V., Wahren B., Wolf H. Use of synthetic oligopeptides in identification and characterization of immunological functions in the amino acid sequence of the envelope protein of HIV-1. J Acquir Immune Defic Syndr. 1989;2(1):21–27. [PubMed] [Google Scholar]
  27. Montalvo E. A., Shi Y., Shenk T. E., Levine A. J. Negative regulation of the BZLF1 promoter of Epstein-Barr virus. J Virol. 1991 Jul;65(7):3647–3655. doi: 10.1128/jvi.65.7.3647-3655.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Murray R. J., Kurilla M. G., Brooks J. M., Thomas W. A., Rowe M., Kieff E., Rickinson A. B. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies. J Exp Med. 1992 Jul 1;176(1):157–168. doi: 10.1084/jem.176.1.157. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Murray R. J., Kurilla M. G., Griffin H. M., Brooks J. M., Mackett M., Arrand J. R., Rowe M., Burrows S. R., Moss D. J., Kieff E. Human cytotoxic T-cell responses against Epstein-Barr virus nuclear antigens demonstrated by using recombinant vaccinia viruses. Proc Natl Acad Sci U S A. 1990 Apr;87(8):2906–2910. doi: 10.1073/pnas.87.8.2906. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Nixon D. F., McMichael A. J. Cytotoxic T-cell recognition of HIV proteins and peptides. AIDS. 1991 Sep;5(9):1049–1059. [PubMed] [Google Scholar]
  31. Packham G., Brimmell M., Cook D., Sinclair A. J., Farrell P. J. Strain variation in Epstein-Barr virus immediate early genes. Virology. 1993 Feb;192(2):541–550. doi: 10.1006/viro.1993.1070. [DOI] [PubMed] [Google Scholar]
  32. Pothen S., Richert J. R., Pearson G. R. Human T-cell recognition of Epstein-Barr virus-induced replication antigen complexes. Int J Cancer. 1991 Nov 11;49(5):656–660. doi: 10.1002/ijc.2910490505. [DOI] [PubMed] [Google Scholar]
  33. Rowe M., Lear A. L., Croom-Carter D., Davies A. H., Rickinson A. B. Three pathways of Epstein-Barr virus gene activation from EBNA1-positive latency in B lymphocytes. J Virol. 1992 Jan;66(1):122–131. doi: 10.1128/jvi.66.1.122-131.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Rowe M., Rowe D. T., Gregory C. D., Young L. S., Farrell P. J., Rupani H., Rickinson A. B. Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells. EMBO J. 1987 Sep;6(9):2743–2751. doi: 10.1002/j.1460-2075.1987.tb02568.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Schendel D. J., Reinhardt C., Nelson P. J., Maget B., Pullen L., Bornkamm G. W., Steinle A. Cytotoxic T lymphocytes show HLA-C-restricted recognition of EBV-bearing cells and allorecognition of HLA class I molecules presenting self-peptides. J Immunol. 1992 Oct 1;149(7):2406–2414. [PubMed] [Google Scholar]
  36. Schepers A., Pich D., Hammerschmidt W. A transcription factor with homology to the AP-1 family links RNA transcription and DNA replication in the lytic cycle of Epstein-Barr virus. EMBO J. 1993 Oct;12(10):3921–3929. doi: 10.1002/j.1460-2075.1993.tb06070.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Schwarzmann F., Prang N., Reichelt B., Rinkes B., Haist S., Marschall M., Wolf H. Negatively cis-acting elements in the distal part of the promoter of Epstein-Barr virus trans-activator gene BZLF1. J Gen Virol. 1994 Aug;75(Pt 8):1999–2006. doi: 10.1099/0022-1317-75-8-1999. [DOI] [PubMed] [Google Scholar]
  38. Steinle A., Nössner E., Schendel D. J. Isolation and characterization of a genomic HLA-Cw6 clone. Tissue Antigens. 1992 Mar;39(3):134–137. doi: 10.1111/j.1399-0039.1992.tb01923.x. [DOI] [PubMed] [Google Scholar]
  39. Sutton J., Rowland-Jones S., Rosenberg W., Nixon D., Gotch F., Gao X. M., Murray N., Spoonas A., Driscoll P., Smith M. A sequence pattern for peptides presented to cytotoxic T lymphocytes by HLA B8 revealed by analysis of epitopes and eluted peptides. Eur J Immunol. 1993 Feb;23(2):447–453. doi: 10.1002/eji.1830230222. [DOI] [PubMed] [Google Scholar]
  40. Zeh H. J., 3rd, Leder G. H., Lotze M. T., Salter R. D., Tector M., Stuber G., Modrow S., Storkus W. J. Flow-cytometric determination of peptide-class I complex formation. Identification of p53 peptides that bind to HLA-A2. Hum Immunol. 1994 Feb;39(2):79–86. doi: 10.1016/0198-8859(94)90105-8. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES